Always good to see brokers raising their targets
Edison report from the 13th Aug
Some snips
"Clinical data from CALM, STORM and CANON trials presented at scientific conferences further highlight the potential efficacy of CAVATAK (oncolytic virus) against a range of cancers using several delivery approaches. While the evidence of CAVATAK’s efficacy as a single agent continues to build, it is also likely to be attractive to big pharma companies seeking complementary therapies to boost immune responses to their checkpoint inhibitors; a Phase Ib trial in combination with ipilimumab (Yervoy) is already underway. We value Viralytics at A$189m or A$1.03 per share."
and
"Valuation: rNPV of A$189m (A$1.03 per share) Our valuation of Viralytics has increased to A$189m, or A$1.03/share (undiluted, previously A$0.80/share) due to the incorporation of the intravesical bladder cancer opportunity, roll forward of the DCF model and continued weakness of the Australian dollar against the US dollar (now US$0.73 per A$ vs 0.78 previously)."
http://www.edisoninvestmentresearch.com/research/report/viralytics7
- Forums
- ASX - By Stock
- VLA
- Broker upgrade
Broker upgrade
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non Executive Director
Simon Kidston
Non Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online